Bologna’s Cellply Secures €7.15 Million to Develop Tools for Faster Immunotherapy and Cell Therapy Development

Why It Matters

The infusion accelerates commercialization of high‑resolution analytics that can streamline regulatory batch release, a bottleneck for immunotherapy manufacturers. Faster, cheaper potency testing could broaden market adoption of advanced therapy medicinal products (ATMPs).

Key Takeaways

• €7.15 M ($7.8 M) funding led by ENEA Tech e Biomedical.
• VivaCyte® offers automated single‑cell imaging for immunotherapy development.
• Capital earmarked for global expansion and next‑gen ATMP QC tools.
• Board adds Miro Venturi, bringing diagnostics scaling expertise.
• Goal: reduce cost and complexity of cell therapy potency assays.

Pulse Analysis

Advanced therapy medicinal products (ATMPs) such as CAR‑T cells and personalized cancer vaccines are reshaping oncology, but their path to market is hampered by labor‑intensive potency testing and batch‑release bottlenecks. High‑resolution, single‑cell analytics can reveal functional heterogeneity that bulk assays miss, enabling manufacturers to fine‑tune manufacturing processes and meet stringent regulatory standards. Cellply’s VivaCyte® platform combines patented microfluidics, AI‑driven image analysis, and end‑to‑end automation to deliver unprecedented cellular phenotyping at scale. By translating complex microscopy data into actionable quality metrics, the system promises to accelerate discovery and streamline production pipelines.

The €7.15 million ($7.8 million) round, led by ENEA Tech e Biomedical and bolstered by CDP Venture Capital’s SAFE conversion, gives Cellply the runway to scale VivaCyte® across Europe, North America, and Asia. The capital will fund regional sales teams, regulatory filings, and the next generation of automated functional testing tools designed for ATMP quality control. Adding industry veteran Miro Venturi to the board brings decades of diagnostics and precision‑medicine experience, positioning the company to navigate complex reimbursement landscapes and forge strategic partnerships with biotech manufacturers.

If Cellply can deliver on its promise to lower assay costs and shorten release timelines, the ripple effect could be profound: smaller biotech firms would gain access to enterprise‑grade QC without prohibitive capital outlays, and larger players could accelerate pipeline throughput, potentially shaving months off clinical development. Competitors such as CytoReason and NanoString are also racing to embed AI‑driven single‑cell profiling into manufacturing, but Cellply’s fully automated workflow differentiates it in a market that values speed and regulatory compliance. Successful commercialization would reinforce Europe’s emerging deep‑tech biotech ecosystem and signal a shift toward data‑centric, precision‑manufacturing in cell therapy.